Clinical Trials
13 trialsNCT04817761 2026-02-18
SPARK-ALL: Calaspargase Pegol in Adults With ALL
Servier
Phase 2/3 Terminated
NCT03870750 2026-01-12
Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases
Fred Hutchinson Cancer Center
Phase 2/3 Terminated
NCT03801525 2024-04-19
ULTRA-V
TG Therapeutics, Inc.
Phase 2/3 Terminated
NCT00630565 2024-01-29
Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
Masonic Cancer Center, University of Minnesota
Phase 2/3 Terminated
NCT03699475 2023-09-29
THRIVE
Bellicum Pharmaceuticals
Phase 2/3 Terminated
NCT02793583 2022-07-21
UNITY-NHL
TG Therapeutics, Inc.
Phase 2/3 Terminated
NCT00967343 2021-06-14
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
Kiadis Pharma
Phase 2/3 Terminated
NCT03547154 2019-08-12
C98026
Merck Sharp & Dohme LLC
Phase 2/3 Terminated
NCT00038805 2018-10-31
Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2/3 Terminated
NCT01588951 2018-08-14
Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2/3 Terminated
NCT00176839 2017-12-05
Stem Cell Transplantation for Hematological Malignancies
Masonic Cancer Center, University of Minnesota
Phase 2/3 Terminated
NCT00714259 2017-07-24
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies
University of Alabama at Birmingham
Phase 2/3 Terminated
NCT00060385 2012-09-24
Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2/3 Terminated